Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Fu
  ChiCTR2000030262		 RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 conclusif

    COVID-19 severe or critically meta-analysis

    Darazam (COVIFERON Interferon beta-1a)
          NCT04343768    		 RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
    		20/20 suggested
    • suggested 1.4-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    Darazam (COVIFERON Interferon beta-1b)
          NCT04343768    		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
    		20/20 inconclusive
      Rahmani
              IRCT20100228003449N2      		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
      		40/40 conclusif
      • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      2 studies excluded by filtering options (2 RCT / 0 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons